Core Insights - Sutro Biopharma has initiated a Phase 1 study for STRO-004, a potential best-in-class Tissue Factor ADC, marking a significant step in its clinical development [1] - The company has selected PTK7 as the target for its first dual-payload candidate, STRO-227, which aims to address difficult-to-treat solid tumors [1][5] - Sutro is hosting a virtual R&D Day to discuss its innovative ADC platform and pipeline, emphasizing its near- and long-term priorities [1][2] Company Overview - Sutro Biopharma is a clinical-stage oncology company focused on developing site-specific and novel-format antibody drug conjugates (ADCs) [1][8] - The company utilizes a proprietary cell-free platform that allows for optimized design of ADCs, enhancing safety and efficacy [3][8] ADC Pipeline Highlights - **Single-Payload ADC Programs** - STRO-004 has entered clinical trials after receiving IND clearance from the FDA, showing promising anti-tumor activity in preclinical models for various cancers [4] - STRO-006, targeting integrin β6, is expected to enter clinical development in 2026, demonstrating a superior pharmacokinetic profile compared to existing ADCs [4] - **Dual-Payload ADC Program** - STRO-227 targets PTK7, which is overexpressed in several cancers, with an IND submission planned for 2026/2027 [5][11] Strategic Collaborations - Sutro is collaborating with Astellas to advance dual-payload immunostimulatory ADCs, with the first program expected to enter clinical trials in early 2026 [6]